Despite a global economic environment characterised by volatility and challenges related to regulation and high costs in Europe, European pharmaceutical and biotech companies remain optimistic about the outlook for profitability. According to a survey conducted by Horváth, an international management consultancy company with a presence on the Romanian market since 2005, 66% of executives in this sector expect profit growth of more than 5% in 2025 and 2026. This positive trend is underpinned by